Overview

Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers

Status:
RECRUITING
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open, single-dose, crossover-design, phase I study to evaluate the pharmacokinetics and safety after co-administration of L03RD1 and L03RD2 or administration of CT-L03 in healthy volunteers.
Phase:
PHASE1
Details
Lead Sponsor:
Celltrion